top of page

Bladder Cancer Treatment in China: Options, Evidence and Hospitals

By

ChinaCureLink

Wed Nov 18 2026

11 min read

4 hours ago
11 min read

Medically reviewed by Dr Eric Wang- ChinaCureLink Team


Bladder cancer treatment in China depends first on whether the cancer is non-muscle-invasive, muscle-invasive or metastatic. Options can include tumor removal through the urethra, treatment placed inside the bladder, bladder-removal surgery with urinary diversion, selected bladder-preserving chemoradiation and systemic medicines. A pathology and staging review should come before choosing a hospital or a newer drug.


For international patients, this guide explains those treatment pathways, a recent Chinese phase III trial, three hospital options and six relevant specialists. It also covers the records, costs and follow-up arrangements needed for an informed second opinion. Treatment access and suitability must be confirmed for the individual case.


Key Takeaways

  1. Stage, grade and prior treatment determine the next decision; non-muscle-invasive and metastatic disease need different plans.

  2. Bladder preservation is an option for selected patients and requires close surveillance; it is not a promise that bladder removal can always be avoided.

  3. HER2-expressing advanced urothelial cancer has new Chinese trial evidence for disitamab vedotin plus toripalimab, with significant treatment risks.

  4. Compare multidisciplinary teams, pathology review, systemic-treatment expertise and urinary diversion or follow-up support.

  5. ChinaCureLink hospital and specialist matching is free. Specialist video second opinions are paid, with fees confirmed before booking.


Table of Contents



Treatment Choices Begin With Stage and Pathology


A transurethral resection of bladder tumor, or TURBT, removes visible tumor through the urethra and provides tissue for diagnosis. The report should identify grade, histological type and whether bladder muscle is present and involved. An incomplete sample or certain high-risk findings may require another resection before the plan is settled.


Non-muscle-invasive bladder cancer: management is based on recurrence and progression risk. TURBT may be followed by medicines placed inside the bladder, such as chemotherapy or BCG immunotherapy. High-risk disease or cancer that does not respond adequately to BCG may require discussion of cystectomy or other evidence-based options. Confirm local availability of any proposed intravesical treatment.


Muscle-invasive localized cancer: radical cystectomy removes the bladder and requires a new route for urine. Eligible patients may receive treatment before or after surgery. Selected patients can consider trimodality treatment: maximal TURBT followed by radiation with concurrent chemotherapy. Multidisciplinary review should compare both approaches where appropriate.


Metastatic or unresectable disease: systemic medicines aim to control disease and symptoms and, where supported, prolong survival. Selection depends on prior drugs, kidney function, performance status and relevant biomarkers. Results from advanced disease should not be used to justify the same regimen for every early-stage tumor.


On a smaller screen, swipe the table horizontally to view every column.


Disease Group

Common Treatment Discussion

Key Decision

Non-muscle-invasive disease

Transurethral resection, risk-adapted intravesical treatment and surveillance

Confirm adequate staging, recurrence risk and response to prior BCG

Muscle-invasive localized disease

Radical cystectomy with urinary diversion and appropriate perioperative therapy; selected trimodality bladder preservation

Compare cancer control, fitness, urinary function and surveillance requirements

Unresectable locally advanced or metastatic disease

Systemic treatment selected by prior therapy, biomarkers, organ function and local approval

Clarify the goal of treatment, expected benefit, toxicity and continuing care


New Chinese Evidence in Advanced Urothelial Cancer


The phase III RC48-C016 trial enrolled 484 patients with previously untreated, HER2-expressing locally advanced or metastatic urothelial cancer. HER2 expression was defined as immunohistochemistry 1+, 2+ or 3+. It compared disitamab vedotin plus toripalimab with gemcitabine plus cisplatin or carboplatin. Median follow-up was 18.2 months.


Median progression-free survival was 13.1 versus 6.5 months; interim median overall survival was 31.5 versus 16.9 months. Tumor response was 76.1% versus 50.2%. Grade 3 or higher treatment-related adverse events occurred in 55.1% versus 86.9%. These endpoints describe different outcomes: a response is not a cure, and a median is not an individual life expectancy.


The open-label, industry-funded study did not compare the combination with every modern regimen, including enfortumab vedotin plus pembrolizumab. Its results concern a selected advanced-disease population, not all bladder cancers. Serious toxicity remains possible, so an oncologist must explain monitoring, alternatives and how symptoms or adverse effects will be managed.


An April 10, 2026 manufacturer regulatory filing reported Chinese approval of disitamab vedotin with toripalimab for HER2-expressing locally advanced or metastatic urothelial carcinoma. The current label, hospital supply, costs and individual eligibility still need confirmation. That indication should not be extended automatically to an early-stage bladder-preservation proposal or clinical-trial use.


Evidence

Reported Finding

Practical Limit

RC48-C016; randomized phase III, 484 patients

Median PFS 13.1 vs 6.5 months; interim median OS 31.5 vs 16.9 months

Previously untreated HER2-expressing advanced urothelial cancer; comparator was platinum-based chemotherapy

Safety in the same trial

Grade 3 or higher treatment-related adverse events: 55.1% vs 86.9%

Serious toxicity remains possible; results do not establish superiority over every modern regimen


Which Treatment Fits Your Diagnosis?

Eligibility depends on condition, medical history and treatment goals. Send your records and we’ll match you with relevant Chinese hospitals and specialists at no cost.

Free matching · Paid video specialist consultations · Fees confirmed before booking


Planning Treatment as an International Patient


Prepare the TURBT or biopsy report, pathology slides or blocks where requested, operation notes, cystoscopy findings, imaging reports and original DICOM files. Include kidney-function results, medicines, allergies, other illnesses and all previous cancer treatment. For prior BCG, record the dates, number of doses and response; a simple statement that “BCG failed” may not establish the relevant category.


A specialist review should answer the clinical question before travel: whether staging is complete, whether cure-directed local treatment is possible, whether bladder preservation is reasonable or which systemic options fit the disease. Send existing HER2 or other relevant biomarker results, but let the treating team determine whether more testing is needed.


Obtain written confirmation of the receiving department, clinician where applicable, campus, interpretation and admission route. For cystectomy, discuss diversion options, stoma support, sexual and urinary function, rehabilitation and the expected recovery plan. A neobladder is a urinary reconstruction, not preservation of the original bladder, and is not suitable for everyone.


Request an itemized estimate covering pathology review, staging, medicines, procedures, admission, diversion supplies and follow-up. Drug approval does not establish insurance coverage or a standard package price. Confirm deposits, potential extra costs and your insurer’s requirements. Our medical trip planning guide and China medical tourism guide cover the wider preparation.


How ChinaCureLink Helps You Compare Appropriate Teams


ChinaCureLink helps organize the diagnosis, pathology, stage and treatment history for assessment and matches the case with up to three appropriate hospitals or specialists. The priority is a team that can address the actual decision, including surgical, medical oncology and radiation oncology input where needed. The receiving clinician makes the clinical recommendation.


Hospital and specialist matching is free. An optional specialist video second opinion is a paid consultation, with fees confirmed before booking. Later coordination can include appointments, records, interpretation arrangements, travel and follow-up; confirm the scope and price in writing. The hospital and specialist matching guide explains the process.


Three Hospitals and Six Specialist Profiles


Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center and West China Hospital are three institutions to compare for urologic oncology services. This is a service-based shortlist, not a bladder-cancer survival ranking. Our China hospital guide explains broader comparison criteria.


The profiles below show relevant clinical interests. They do not establish appointment availability or that a named doctor will perform an operation. Ask which specialist team will assess the case and how surgery, systemic therapy and radiotherapy will be coordinated.


1. Fudan University Shanghai Cancer Center


Founded in 1931, Fudan University Shanghai Cancer Center is a specialist cancer hospital affiliated with Fudan University. Its urologic oncology department was established in 2002 and combines surgical, multidisciplinary and clinical-research services.


For bladder cancer, the relevant strength is the ability to connect pathology and staging with the choice between local treatment and systemic therapy. Its documented services include bladder investigations and intravesical treatment, alongside surgical and urologic oncology expertise. A treatment discussion should address both cancer control and life after treatment.


The Xuhui and Pudong campuses should not be treated as interchangeable appointment locations. The photograph shows Pudong. Confirm which campus provides the relevant clinician, procedure, infusion or radiotherapy service, and how the team will coordinate the full plan.



Shanghai · Confirm Xuhui or Pudong Appointment Campus · Grade III Class A · Public Specialist Hospital


Urologic cancer surgery · Systemic treatment · Multidisciplinary care


Known for: Specialist cancer care with surgical and drug-treatment expertise in urologic oncology.



2. Sun Yat-sen University Cancer Center


Established in 1964, Sun Yat-sen University Cancer Center combines cancer care, research and education. Its Guangzhou campuses include Yuexiu and Huangpu; the photograph shows Huangpu. The receiving clinic and treatment location must be confirmed rather than inferred from a hospital name.


Its urologic oncology profiles explicitly describe bladder cancer surgery and comprehensive treatment. This is relevant to patients weighing cystectomy, urinary reconstruction, systemic treatment or a second opinion on a difficult sequence of care. The right assessment also draws on pathology, imaging and radiation oncology when appropriate.


Ask how the proposed plan accounts for prior TURBT, intravesical therapy, kidney function and any previous systemic medicines. A specialist appointment should produce a reasoned recommendation and follow-up plan, rather than simply an offer of a technically advanced operation.



Guangzhou · Confirm Yuexiu or Huangpu Appointment Campus · Grade III Class A · Public Specialist Hospital


Bladder cancer surgery · Multidisciplinary treatment · Urothelial cancer expertise


Known for: Specialist cancer services with documented bladder-cancer surgical and multidisciplinary expertise.



3. West China Hospital, Sichuan University


West China Hospital traces its history to 1892 and is affiliated with Sichuan University. Its comprehensive-hospital setting brings together urologic surgery, oncology, pathology, imaging and support for other medical conditions that may affect cancer treatment.


Its published urologic and oncology service descriptions include bladder cancer surgery, systemic-treatment research and multidisciplinary care. This makes it an option to compare when the decision involves both local treatment and another medical issue, rather than a single procedure in isolation.


For an overseas patient, establish the exact urologic oncology pathway and how medical and radiation oncology will contribute where needed. Ask whether the proposed operation or bladder-preserving approach is supported by the staging and overall health assessment, and how follow-up will be transferred to a home clinician.



Chengdu · Confirm Appointment Campus · Grade III Class A · Public University Hospital


Urologic surgery · Comprehensive hospital support · Multidisciplinary oncology


Known for: A comprehensive hospital setting for urologic surgery and coordinated cancer care.



A Recent Chinese Patient Report and Its Limits


A June 2026 case report described a 79-year-old man with high-grade muscle-invasive urothelial cancer, suspected pelvic nodal involvement and HER2 staining of 1+. He declined radical cystectomy and received disitamab vedotin plus toripalimab. After six cycles, repeat transurethral sampling of the tumor bed found no viable tumor.


The authors reported mild fatigue and nausea and no clinical or radiological recurrence at their latest follow-up in June 2025. Importantly, the response assessment came from tumor-bed sampling, not removal and examination of the whole bladder and lymph nodes. It cannot establish that every original disease site was eradicated or that cure was achieved.


This single-patient report illustrates a possible response, not a standard bladder-preservation strategy or evidence that cystectomy can safely be omitted. Its treatment period preceded the later approval filing. Decisions about local control and ongoing surveillance require multidisciplinary assessment.


Protecting Treatment Continuity After Returning Home


Bladder-preserving care requires a defined surveillance plan, including cystoscopy and other assessments appropriate to the case. Recurrence or persistent disease may lead to a different treatment recommendation, including salvage surgery. Agree before travel who will perform follow-up and how results will reach the treating team.


After cystectomy, obtain written guidance for the urinary diversion, supplies, kidney-function monitoring and recovery. For systemic treatment, agree where infusions, blood tests and toxicity assessment will occur. Collect the pathology, imaging, operation or treatment summary, medicine names and doses, and a clear escalation plan for new symptoms.


You Contact the Hospital vs. via ChinaCureLink


Both routes can work. Many large Chinese hospitals have international departments, and some patients go direct. Here is what each route looks like, step by step.


Swipe the table horizontally on smaller screens to view all columns.


What to Arrange

Contacting Hospitals Yourself

With ChinaCureLink

Hospital and specialist choice

Research and contact suitable teams yourself

✓ Diagnosis-based hospital and specialist matching — free

Appointments

Arrange times and follow up with each team

✓ Support with scheduling and hospital communication

Medical records

Prepare and translate the required documents

✓ Help organizing records for specialist review

Language assistance

Check the hospital’s interpreter arrangements

✓ Help arranging interpretation for medical discussions

Travel and accommodation

Book your travel and stay independently

✓ Coordination after you choose to proceed

Local coordination

Check what support the hospital offers

✓ Coordinator support during your stay

Continuing care

Request records and arrange follow-up yourself

✓ Help coordinating records for your home doctor

Hospital quote

Ask the hospital for an itemized estimate

✓ Help obtaining the quote and applying for an international discount, where available


Hospital and specialist matching is free. Specialist video consultations and later on-site services have separate fees, confirmed before booking. Any hospital discount depends on the hospital and individual quotation.


Start With Free Hospital and Specialist Matching

ChinaCureLink represents patients, not hospitals. Hospital and specialist matching is free, and travel coordination begins only after you choose to proceed.

Free matching · Paid video specialist consultations · Fees confirmed before booking


Next step: Obtain a diagnosis-matched assessment, compare the written recommendations and confirm costs and follow-up before making travel arrangements.


Get a Second Opinion


For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.


Hospital and specialist matching is free. Video second opinions are paid specialist consultations, with fees confirmed before booking.




What Patients Say About ChinaCureLink & Medebound HEALTH


Medebound HEALTH company and patient feedback — bladder cancer treatment in China guide

China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.



Frequently Asked Questions


What are the main options for bladder cancer treatment in China?

Bladder cancer treatment in China depends on stage, grade, prior treatment and overall health. Options include TURBT, intravesical therapy, cystectomy with urinary diversion, selected bladder-preserving chemoradiation and systemic medicines. Begin with pathology and staging review before choosing a treatment or hospital.


Can bladder cancer be treated without removing the bladder?

Some non-muscle-invasive cancers are managed with TURBT and intravesical therapy. Selected muscle-invasive cancers may be treated with maximal TURBT and concurrent chemoradiation. Suitability requires multidisciplinary review and close surveillance, with salvage surgery considered if needed. A drug response alone does not prove that cystectomy can safely be omitted.


Is disitamab vedotin plus toripalimab available for bladder cancer in China?

An April 2026 manufacturer regulatory filing reported Chinese approval for HER2-expressing locally advanced or metastatic urothelial carcinoma. The current indication, hospital supply, costs and individual suitability must be confirmed. This does not automatically authorize the combination for every early-stage or bladder-preservation setting.


Talk It Through Before You Decide

Start with free hospital and specialist matching. We’ll review your situation and match you with relevant hospitals and specialists at no cost. Paid video second opinions are available, with fees confirmed before booking.

Free matching · Paid video specialist consultations · Fees confirmed before booking



About ChinaCureLink


ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.


We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.


ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.


References



Disclaimer


This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.


You may also like:



bottom of page